Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy

Antonio Di Biagio, A. Cozzi-Lepri, Roberta Prinapori, G. Angarano, A. Gori, Tiziana Quirino, Andrea De Luca, Andrea Costantini, C. Mussini, G. Rizzardini, Antonella Castagna, Andrea Antinori, Antonella D. Monforte, Marco Moroni, M. Andreoni, G. Angarano, A. Antinori, A. D'Arminio Monforte, F. Castelli, R. CaudaG. Di Perri, Massimo Galli, R. Iardino, Giuseppe Ippolito, Adriano Lazzarin, Carlo Federico Perno, F. Von Schloesser, P. Viale, Antonella d'Arminio Monforte, A. Antinori, A. Castagna, F. Ceccherini-Silberstein, A. Cozzi-Lepri, Enrico Girardi, S. Lo Caputo, Cristina Mussini, M. Puoti, M. Andreoni, Adriana Ammassari, A. Antinori, Claudia Balotta, Alessandra Bandera, Paolo Bonfanti, Stefano Bonora, M. Borderi, Andrea Calcagno, Leonardo Calza, Maria Rosaria Capobianchi, A. Castagna, Francesca Ceccherini-Silberstein, Antonella Cingolani, Paola Cinque, Alessandro Cozzi-Lepri, Antonella d'Arminio-Monforte, A. De Luca, A. Di Biagio, Enrico Girardi, Nicola Gianotti, Andrea Gori, Giovanni Guaraldi, Giuseppe Lapadula, Miriam Lichtner, S. Lo Caputo, Giordano Madeddu, F. Maggiolo, G. Marchetti, S. Marcotullio, L. Monno, Cristina Mussini, M. Puoti, E. Quiros-Roldan, R. Rossotti, S. Rusconi, Maria Mercedes Santoro, A. Saracino, M. Zaccarelli, A. Cozzi-Lepri, I. Fanti, Laura Galli, Patrizia Lorenzini, A. Rodano, M. Shanyinde, A. Tavelli, Andrea Giacometti, Andrea Costantini, S. Mazzoccato, G. Angarano, L. Monno, C. Santoro, F. Maggiolo, C. Suardi, P. Viale, E. Vanino, G. Verucchi, Francesco Castelli, E. Quiros Roldan, C. Minardi, T. Quirino, C. Abeli, P. E. Manconi, P. Piano, J. Vecchiet, K. Falasca, L. Sighinolfi, D. Segala, F. Mazzotta, S. Lo Caputo, Giovanni Cassola, Claudio Viscoli, A. Alessandrini, R. Piscopo, G. Mazzarello, C. Mastroianni, V. Belvisi, Paolo Bonfanti, I. Caramma, A. Chiodera, A. P. Castelli, Massimo Galli, A. Lazzarin, G. Rizzardini, Massimo Puoti, A. d'Arminio Monforte, Annalisa Ridolfo, R. Piolini, Antonella Castagna, S. Salpietro, L. Carenzi, M. C. Moioli, C. Tincati, G. Marchetti, C. Mussini, C. Puzzolante, Andrea Gori, Giuseppe Lapadula, N. Abrescia, Antonio Chirianni, G. Borgia, M. G. Guida, M. Gargiulo, Ivan Gentile, R. Orlando, F. Baldelli, D. Francisci, G. Parruti, T. Ursini, G. Magnani, M. A. Ursitti, R. Cauda, M. Andreoni, A. Antinori, Vincenzo Vullo, Antonella Cingolani, A. D'avino, L. Gallo, Emanuele Nicastri, Rosa Antonietta Acinapura, M. Capozzi, Raffaella Libertone, G. Tebano, Mauro Zaccarelli, F. Viviani, Lolita Sasset, M. S. Mura, Giuseppe Madeddu, Andrea De Luca, Barbara Rossetti, P. Caramello, Giovanni Di Perri, G. C. Orofino, S. Bonora, M. Sciandra, Matteo Bassetti, A. Londero, G. Pellizzer, Vinicio Manfrin

Research output: Contribution to journalArticle

Abstract

Background: Study aim was to estimate the rate and identify predictors of discontinuation of first combination antiretroviral therapy (cART) in recent years. Methods: Patients who initiated first cART between January 2008 and October 2014 were included. Discontinuation was defined as stop of at least 1 drug of the regimen, regardless of the reason. All causes of discontinuation were evaluated and 3 main endpoints were considered: toxicity, intolerance, and simplification. Predictors of discontinuation were examined separately for all 3 endpoints. Kaplan-Meier analysis was used for the outcome discontinuation of ≥1 drug regardless of the reason. Cox regression analysis was used to identify factors associated with treatment discontinuation because of the 3 reasons considered. Results: A total of 4052 patients were included. Main reason for stopping at least 1 drug were simplification (29%), intolerance (21%), toxicity (19%), other causes (18%), failure (8%), planned discontinuation (4%), and nonadherence (2%). In a multivariable Cox model, predictors of discontinuation for simplification were heterosexual transmission (P = 0.007), being immigrant (P = 0.017), higher nadir lymphocyte T CD4+ cell (P = 0.011), and higher lymphocyte T CD8+ cell count (P = 0.025); for discontinuation due to intolerance: the use of statins (P = 0.029), higher blood glucose levels (P = 0.050). About toxicity: higher blood glucose levels (P = 0.010) and the use of zidovudine/lamivudine as backbone (P = 0.044). Conclusions: In the late cART era, the main reason for stopping the initial regimen is simplification. This scenario reflects the changes in recommendations aimed to enhance adherence and quality of life, and minimize drug toxicity.

Original languageEnglish
Pages (from-to)263-271
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume71
Issue number3
DOIs
Publication statusPublished - 2016

    Fingerprint

Keywords

  • Antiretroviral therapy
  • Discontinuation
  • First-line therapy
  • HIV-1
  • Resumption treatment
  • Single-tablet regimen

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Di Biagio, A., Cozzi-Lepri, A., Prinapori, R., Angarano, G., Gori, A., Quirino, T., De Luca, A., Costantini, A., Mussini, C., Rizzardini, G., Castagna, A., Antinori, A., Monforte, A. D., Moroni, M., Andreoni, M., Angarano, G., Antinori, A., D'Arminio Monforte, A., Castelli, F., ... Manfrin, V. (2016). Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy. Journal of Acquired Immune Deficiency Syndromes, 71(3), 263-271. https://doi.org/10.1097/QAI.0000000000000849